Company profile:
Founded in 2007, Clover Biopharmaceuticals is a global biotechnology company in the clinical trial stage, dedicated to developing new vaccines and biological therapeutic candidates for infectious diseases, as well as cancer and autoimmune diseases. The main indications for its products in various therapeutic areas are COVID-19, malignant ascites, and ankylosing spondylitis.
The group introduced the Trimer-TagTM patented technology platform to become a COVID-19 vaccine development company, and has developed the core product SCB-2019 to address the COVID-19 epidemic caused by SARS-CoV-2. They have also developed another core product, SCB-808, for the treatment of rheumatic diseases.
The group's product pipeline includes six Trimer-TagTM subunit candidate vaccines, including SCB-2019, two Trimer-TagTM tumor treatment candidate products, and three Fc fusion protein candidate products, covering 13 indications.
Research and development status of the company's main products and products under development:
Prospectus Information:
Financial situation:
All the company's products are in the research and development, clinical trials, and registration stages of candidate products, with no commercialized products yet. Therefore, it is currently in a loss-making stage, with a loss of 485.83 million RMB in 2019, 912 million RMB in 2020, and as of April 30, 2021, the loss for the most recent year has further expanded to 1.673 billion...